<DOC>
	<DOCNO>NCT02045966</DOCNO>
	<brief_summary>The primary purpose study assess effect Daclatasvir/Asunaprevir/BMS-791325 fix dose combination ( FDC ) tablet pharmacokinetics cocktail CYP transporter probe substrates assess effect DCV 3DAA FDC [ DCV 3DAA FDC = fix dose combination formulation 3 direct-acting antiviral ( 3DAA ) ( DCV 30 mg , ASV 200 mg , BMS-791325 75 mg ) ] + BMS-791325 75-mg single-agent tablet Pharmacokinetic ( PK ) cocktail CYP transporter probe substrate .</brief_summary>
	<brief_title>Study Determine Potential DDIs When Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet ( FDC ) Coadministered With Cocktail Cytochrome P450 ( CYP ) Probe Substrates Transporter Probe Substrates ( Digoxin Pravastatin ) Healthy Subjects</brief_title>
	<detailed_description>IND number : 79,599 101,943 Primary purpose : Other : study conduct investigate potential drug-drug interaction ( DDIs ) Daclatasvir/Asunaprevir/BMS-791325 FDC formulation coadministered cocktail cytochrome P450 ( CYP ) probe substrate ( Caffeine , Metoprolol , Montelukast , Flurbiprofen , Omeprazole , Midazolam ) transporter probe substrate ( Digoxin Pravastatin ) healthy subject . It also intend characterize PK Daclatasvir ( DCV ) , Asunaprevir ( ASV ) , BMS-791325 , major metabolite , BMS-794712 , steady state .</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Flurbiprofen</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Healthy subject determine clinically significant deviation normal medical history , physical examination , vital sign measurement , 12lead ECG measurement , clinical laboratory test result Body mass index ( BMI ) 18.0 32.0 kg/m2 , inclusive . BMI = weight ( kg ) / [ height ( ) ] 2 Men woman , age 18 45 year , inclusive Women must childbearing potential , must breastfeed Any significant acute chronic medical illness History important arrhythmia include , limited , ventricular fibrillation , ventricular tachycardia , complete atrioventricular ( AV ) block , WolffParkinsonWhite syndrome History cardiac arrhythmia palpitation associate presyncope syncope , history unexplained syncope History heart disease History prolong QT interval torsades de pointes ( TdP ) History hypokalemia Family history sudden cardiac death young age , TdP , Long QT syndrome History asthma , bronchospasm , sleep apnea History rhabdomyolysis History bleed disorder History Raynaud 's disease History peptic ulcer disease significant gastrointestinal bleed History biliary disorder , include Gilbert 's disease DubinJohnson disease Current recent ( within 3 month study drug administration ) gastrointestinal disease Any major surgery within 4 week study drug administration Any gastrointestinal surgery ( include cholecystectomy ) could impact upon absorption study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>